Key result
Recent glucocorticoid exposure in rheumatoid arthritis is linked to ~53% higher odds of SSRI initiation.
Why the study?
The immune system might affect the development of anxiety disorders through unclear mechanisms, prompting investigation into whether glucocorticoid use is associated with SSRI initiation.
Does glucocorticoid exposure increase the risk of SSRI initiation in patients with rheumatoid arthritis?
Case-Control (n=7,276)
Does glucocorticoid exposure increase the risk of SSRI initiation in patients with rheumatoid arthritis?
Glucocorticoid exposure in rheumatoid arthritis patients is associated with an increased risk of initiating SSRI therapy, highlighting the need to monitor for mood symptoms during and after treatment.
Answers are grounded in this paper and cite their sources.
Glucocorticoid use was associated with higher SSRI initiation in RA; leaves open causal mental health effects and needs prospective confirmation.
Aim The immune system might affect the development of anxiety disorders, though mechanisms remain unclear. This nested case–control study investigates whether use of glucocorticoids, potent immunosuppressants, is associated with SSRI initiation (a proxy for pharmacologically treated mental disorders, predominantly depression and/or anxiety). Methods The study was nested within a cohort of primary care patients with a rheumatoid arthritis (RA) diagnosis between 1 January 2010 and 31 December 2019, commonly treated with glucocorticoids, from the UK Clinical Practice Research Datalink Aurum. RA patients receiving a first selective serotonin reuptake inhibitor (SSRI) prescription, the first‐line treatment for anxiety disorders (cases), were matched on sex, year of birth, RA duration and GP practice to RA patients with no SSRI initiation (controls). Patients with prior depression diagnosis or antidepressant use were excluded. Associations between glucocorticoid exposure and SSRI initiation were estimated with conditional logistic regression, assessing timing, prednisone‐equivalent cumulative dose and prescription count. Results From a cohort of 128 595 RA patients, 3134 cases and 4142 matched controls were identified. Recent (adjusted odds ratio 1.53, 95% CI 1.32–1.78) and past glucocorticoid exposure (adjusted odds ratio 1.40, 95% CI 1.07–1.83) were associated with a significantly increased SSRI initiation risk, regardless of cumulative dose or prescription count the year before the index date. Conclusion Glucocorticoid exposure in RA patients was associated with increased odds of SSRI initiation. While residual confounding by disease severity cannot be excluded, clinicians should remain alert to mood symptoms during and after glucocorticoid therapy. Replication in other glucocorticoid‐treated populations is warranted.
No takes yet. Share an insight, caveat, or question.
Heesbeen et al. (2026) conducted a case-control in Rheumatoid arthritis (n=7,276). Glucocorticoid exposure vs. No recent glucocorticoid exposure was evaluated on SSRI initiation (OR 1.53, 95% CI 1.32-1.78). Recent glucocorticoid exposure in patients with rheumatoid arthritis was associated with increased odds of SSRI initiation.
Synapse has enriched 10 related papers. Consider them for comparative context: